Journal of Clinical & Experimental Pharmacology

Patients response after using Antibodies monoclonal for multiple sclerosis and migraine

17^th International Conference on PHARMACOLOGY AND DRUG DISCOVERY

June 15-16, 2023 | Rome, Italy

Zeyad Nimer

Burjeel Hospital, UAE

Scientific Tracks Abstracts: J Clin Exp Pharmacol

Abstract:

Introduction: Monoclonal antibodies (MABs) are one of the preferred treatments for multiple sclerosis (MS) due to their target specificity and usually high efficacy. These have usually targeted the immune system, which plays a key role in the pathogenesis of MS, especially during the early inflammatory stages. Natalizumab is monoclonal antibody currently licensed for relapsing-remitting MS. It works by targeting lymphocyte migration across the blood— brain barrier, an early step in MS lesion formation. Patient response for multiple sclerosis MABs: Natalizumab, is a medication used to treat multiple sclerosis . It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion every 28 days. Recommended dose: 300-mg infusion every 4 weeks. Patient response and common side effect: • Pain, Dry skin, Itching Rash Swelling, Warmth or heat Redness. • Patient review medication effective many patient feedbacks is about weight gain and dry skin. • Patients they are using botulinum toxin for migraine when convert to Galcanezumab injection they are facing sever vomiting and nausea after one day from taking injection. • Last thing cost wise first dos will 240 mg that mean 2 injection and Galcanezumab injection available in 120 mg for 1 injection so it will be costly for the patient.price for 1 injection is 604$.

Biography :

Dr. Zeyad Nimer is pharmacist at Burjeel Hospital in Dubai, UAE.